ATTEC-Based Autophagic Elimination of HBV Core Protein Achieves Potent Viral Suppression

Abstract HBV core protein (HBc) plays key roles in the viral lifecycle and hepatocarcinogenesis. While core protein allosteric modulators (CpAMs) have emerged as promising therapeutic agents, they are confronted with the issue of emerging drug resistance and lack the ability to degrade HBc. To surmount these challenges, by leveraging the class II CpAM NVR3-778 and an LC3 ligand ispinesib, we identified TK-96, a first-in-class autophagy-tethering compound (ATTEC) degrader, which induces the degradation of wild-type and drug-resistant HBc via the autophagic-lysosomal pathway. Remarkably, TK-96 exhibited subnanomolar antiviral potency in HepAD38 and HBV-infected HLCZ01 cells, indicating a more than 150-fold improvement in potency compared to NVR3-778. Furthermore, oral administration of TK-96 significantly inhibited viral replication and decreased hepatic HBc, as well as serum HBeAg and HBsAg levels, in an HBV carrier mouse model. Collectively, this study identifies a highly potent HBc degrader and underscores ATTEC-mediated degradation as a novel strategy for anti-HBV therapeutics.

Authors

Institutions

Publication Details

Journal
Journal of Medicinal Chemistry
Published
2026-11-17
DOI
https://doi.org/10.1021/acs.jmedchem.6c01032
Primary Topic
Hepatitis B Virus Studies
Type
article
Field-Weighted Citation Impact
0.00

Funders

Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

ATTEC-Based Autophagic Elimination of HBV Core Protein Achieves Potent Viral Suppression

Baohu Li, Hui Xu, Caiyue Ren, Xinyong Liu et al.
7 links
Journal of Medicinal Chemistry
Hepatitis B Virus Studies
article

ATTEC-Based Autophagic Elimination of HBV Core Protein Achieves Potent Viral Suppression

Baohu Li, Hui Xu, Caiyue Ren, Xinyong Liu, Peng Zhan, Chunhong Ma, Kai Tang, Lifen Gao, Yutong Dou, Shujing Xu, Zhuanchang Wu, Xiaohong Liang, Yang Sun, Zhendong Fu, Kai Wang, Renhui Sun, Shuo Wang, Jing Li
article en

Abstract

Abstract HBV core protein (HBc) plays key roles in the viral lifecycle and hepatocarcinogenesis. While core protein allosteric modulators (CpAMs) have emerged as promising therapeutic agents, they are confronted with the issue of emerging drug resistance and lack the ability to degrade HBc. To surmount these challenges, by leveraging the class II CpAM NVR3-778 and an LC3 ligand ispinesib, we identified TK-96, a first-in-class autophagy-tethering compound (ATTEC) degrader, which induces the degradation of wild-type and drug-resistant HBc via the autophagic-lysosomal pathway. Remarkably, TK-96 exhibited subnanomolar antiviral potency in HepAD38 and HBV-infected HLCZ01 cells, indicating a more than 150-fold improvement in potency compared to NVR3-778. Furthermore, oral administration of TK-96 significantly inhibited viral replication and decreased hepatic HBc, as well as serum HBeAg and HBsAg levels, in an HBV carrier mouse model. Collectively, this study identifies a highly potent HBc degrader and underscores ATTEC-mediated degradation as a novel strategy for anti-HBV therapeutics.

Journal of Medicinal Chemistry
Shandong University (CN), Shandong First Medical University (CN)
National Natural Science Foundation of China, Natural Science Foundation of Shandong Province, Taishan Scholar Foundation of Shandong Province, Postdoctoral Innovation Project of Shandong Province, Science and Technology Support Plan for Youth Innovation of Colleges and Universities of Shandong Province of China
Good health and well-being
Hepatitis B Virus Studies
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon